144 ·Filed May 12, 2026

PTGX

Protagonist Therapeutics, Inc
BEARISH
Impact 5/10
Horizondays Processed4mo ago SEC0001968582-26-000430
Form 144 — notice of proposed sale of securities
Actionable Insight ▼ Bearish

CEO selling $7.76M via Form 144 is a notable insider disposition. While the sale is small relative to market cap, the CEO's intent to sell a meaningful portion of his holdings (1.2% of known position) warrants monitoring. Watch for actual Form 4 filings to confirm execution and any subsequent insider buying patterns.

DirectionBearish
Confidencemedium
Horizondays
Final — all horizons settled through T+60d
PTGX ▲ +40.42% at T+60d
SHORT call ✗ call lost -40.42% · α vs SPY -35.98% · entry $103.88 → $145.87
Entry anchored
May 12, 03:59 PM ET
via exchange tick
T+1d
0.00%
call 0.00% · α -0.00%
$103.88
settled 5mo ago
T+5d
-5.30%
call +5.30% · α +4.15%
$98.37
settled 5mo ago
T+20d
+5.69%
call -5.69% · α -6.30%
$109.79
settled 4mo ago
T+60d
+40.42%
call -40.42% · α -35.98%
$145.87
settled 8w ago

Price Chart

Loading chart...

Executive Summary

CEO Dinesh Patel filed a Form 144 to sell 75,000 shares (~$7.76M at the filing date) via J.P. Morgan. This is a material insider sale by the CEO, representing about 1.2% of his known holdings and 0.1% of market cap. The sale follows an option exercise and comes amid strong analyst consensus (89% bullish) and a $6.7B market cap.

Key Facts

  • CEO Dinesh Patel filed Form 144 to sell 75,000 shares of common stock.
  • Approximate dollar value of proposed sale: $7,762,500.
  • Shares to be sold via J.P. Morgan Securities LLC.
  • Patel's total beneficial ownership after sale: ~64,311,373 shares.
  • Sale follows an option exercise of 75,000 shares on the same date.
  • Filing date: May 12, 2026.
  • Recent insider activity (30d): 3 sells totaling $4.4M.
  • Market cap: $6.7B; analyst consensus 89% bullish.

Financial Impact

CEO proposes to sell ~$7.76M worth of stock, ~0.12% of market cap.

dilutioninsider holdings

Risk Factors

  • Insider selling by CEO may signal lack of confidence in near-term prospects.
  • Sale is not yet executed; Form 144 is an intent to sell.
  • Option exercise suggests shares were acquired at lower cost, reducing signaling weight.

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
89% bullish (19 analysts)

Investment Themes

Biotech & Drug Discovery

Documents Analyzed

This report is based on 3 SEC documents filed with EDGAR.

DocumentAccession Number
144 Filing (Primary)0001968582-26-000430
Document: 0001968582-26-000430-index.html0001968582-26-000430
Document: 0001968582-26-000430.txt0001968582-26-000430
8 reports for PTGX
Performance horizon

Track record builds as more directional reports settle.

Filters
Rows
Reports for PTGX — sortable, filterable
TypeNow
Aug 10, 2026
7w ago
144
BEARISH ★ 5/10
$148.29 $145.09▲ +2.16%▲ +1.10%$139.93 (+5.64%)
Jun 18, 2026
15w ago
8-K
NEUTRAL ★ 3/10
$115.03 $140.91▲ +22.50%▲ +22.65%$139.93 (+21.65%)
Jun 12, 2026
16w ago
Institutional Cluster
MIXED ★ 5/10
$109.78 $131.42▲ +19.71%▲ +17.93%$139.93 (+27.46%)
May 12, 2026
20w ago
144
BEARISH ★ 5/10
$103.88 $109.79▼ −5.69%▼ −6.30%$139.93 (−34.70%)
May 8, 2026
21w ago
Insider Cluster
NEUTRAL ★ 4/10
$99.36 $97.38▼ −1.99%▼ −2.02%$139.93 (+40.83%)
May 8, 2026
21w ago
Insider Cluster
NEUTRAL ★ 5/10
$99.36 $97.38▼ −1.99%▼ −2.02%$139.93 (+40.83%)
May 5, 2026
21w ago
8-K
BULLISH ★ 7/10
$103.97 $95.41▼ −8.23%▼ −11.01%$139.93 (+34.59%)
Feb 25, 2026
31w ago
8-K
MIXED ★ 6/10
$87.10 $104.31▲ +19.76%▲ +25.00%$139.93 (+60.65%)
Showing 8 of 8

US Market Status

Market Open — Closes in 2h 48m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access